GlobeNewswire by notified

Fingerprints announces that Feitian has selected Fingerprints’ next-generation T-Shape™ (T2) solution for their biometric cards

Share

World-leading biometrics company, Fingerprint Cards AB (Fingerprints™) and Feitian, a global leading provider of cyber security products and solutions, are happy to announce that they are continuing their long-lasting relationship by bringing to market biometric cards based on Fingerprints' next generation T-Shape™ (T2) module and BEP-software platform, aimed at the payment and access segments.

The T2 solution has ultra-low power consumption, and its robust biometric performance was recently demonstrated by achieving compliance with Mastercard’s new Fingerprint Sensor Evaluation Process. This new solution is even simpler to integrate into the standard automated card manufacturing process, using the proven and accepted T-Shape packaging delivered in dual row. For card manufacturers, this means higher throughput, reduced waste and lower embedding costs.

“Based on our long-standing partnership with Feitian, we are pleased to collaborate on this biometric solution together with them. Feitian has once more chosen to work with us at Fingerprints and our proven biometric solution, which will guarantee high performance, quality, and security. I strongly believe that this next-generation solution has the potential to be a gamechanger in the biometric smartcard industry, delivering improved cost-efficiency, increased image quality and transaction speed as well as improved power efficiency”, says Michel Roig, President of Payments & Access at Fingerprints.

“Once again, we have chosen biometric technology from Fingerprints, as they have the leading biometric solution on the market. The collaboration resulting in this next generation biometric payment and access cards will ensure a product with a wide range of possibilities for our customers’ needs“, says Yan Yan, Vice President at Feitian.

More information about Fingerprints’ payment solutions.

For further information, please contact:
Michel Roig, President Payments & Access

Investor Relations:
+46(0)10-172 00 10, investrel@fingerprints.com

Press:
+46(0)10-172 00 20, press@fingerprints.com

About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website, read our blog, and follow us on Twitter. Fingerprints is listed on Nasdaq Stockholm (FING B).

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 202423.4.2024 08:15:00 CEST | Press release

PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings of Shareholders on Thursday, 23 May 2024. The annual report for the financial year 2023 has been published on Sequana Medical's website and can be accessed here. The items on the agendas of the meetings include (among other) the proposed approval of a number of resolutions relating to the financial year ended 31 December 2023, the proposed approval of the revised remuneration policy, the proposed reappointment of the statutory auditor, the application of Article 7:151 of t

KBC Group: Update regarding the KBC Group share buyback programme23.4.2024 08:00:00 CEST | Press release

Within the framework of the share buyback programme announced on 10 August 2023 after trading hours, KBC Group NV wishes to advise that the following transactions took place on Euronext Brussels’ regulated market between 15 April 2024 and 19 April 2024, included: Date No. of shares Total price Average price Lowest price Highest price 15-04-2024 72 000 € 4 947 120 € 68.71 € 68.40 € 69.24 16-04-2024 75 000 € 5 071 792 € 67.62 € 67.28 € 68.00 17-04-2024 72 000 € 4 941 259 € 68.63 € 67.90 € 69.24 18-04-2024 70 000 € 4 883 179 € 69.76 € 69.08 € 70.00 19-04-2024 70 000 € 4 854 325 € 69.35 € 68.20 € 69.78 Following these transactions, the total number of own shares held by KBC Group NV within the framework of the share buyback programme amounted to 14 844 378 on 19 April 2024, for a total consideration of € 883 158 497. This information is also available at https://www.kbc.com/en/share-buy-back Attachment 20240423-pb-buyback-en

Garry Menzel joins GHO Capital as Operating Partner23.4.2024 08:00:00 CEST | Press release

Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR² Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering healthcare companies London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner. Garry brings a unique blend of scientific, strategic, investment and operating skills with diverse experiences from more than 25 years of building healthcare businesses and leading high-performing teams. Most recently he was President and Chief Executive Officer of immunotherapy company TCR² Therapeutics, leading it from concept to clinical trial success before its merger with Adaptimmune (Nasdaq: ADAP) in March 2023 where he became a member of the Board. Prior to TCR² Therapeutics, Garry was the Chief Financial Officer of Da

Innofactor Plc’s Interim Report for January 1–March 31, 2024 (IFRS)23.4.2024 08:00:00 CEST | Press release

Innofactor Plc Interim Report April 23, 2024, at 9:00 Finnish time Innofactor increased its net sales in the first quarter of 2024 in spite of the continued challenging market situation January–March 2024 in brief: Net sales were approximately EUR 21.2 million (2023: 20.2), representing an increase of 4.8%The operating margin was approximately EUR 2.6 million (2023: 2.5), which shows an increase of 4.6% Operating profit was EUR 1.8 million (2023: 1.7), representing an increase of 7.3%The order backlog at the end of the review period was EUR 68.8 million (2023: 76.3), representing a decrease of 9.8% Key figures of the group, IFRS . Jan 1–Mar 31, 2024Jan 1–Mar 31, 2023Change Net sales, EUR thousand 21,186 20,223 4.8% Growth of net sales 4.8% 19.2% Operating result before depreciation and amortization (EBITDA), EUR thousand 2,601 2,487 4.6% percentage of net sales 12.3% 12.3% Operating profit/loss (EBIT), EUR thousand 1,836 1,712 7.3% percentage of net sales 8.7% 8.5% Earnings before taxe

The new UNIQLO x Marimekko collaboration collection brings joyful patterns to a summer picnic23.4.2024 08:00:00 CEST | Press release

Marimekko Corporation, Press release, 23 April 2024 at 9.00 a.m. EEST Finnish lifestyle design house Marimekko and global apparel retailer UNIQLO will launch a new limited-edition collaboration collection in May 2024. The collection is made of simple and comfortable UNIQLO pieces and Marimekko’s timeless archive patterns that showcase the brand’s art of printmaking. The UNIQLO x Marimekko Summer 2024 limited-edition collection includes items for all ages from women to children and babies. The assortment offers a wide array of comfortable dresses, T-shirts and skirts. To perfect the looks, the line also features matching accessories, including the popular round mini shoulder bags in different Marimekko prints. “The overarching theme for this collection is the idea of a joyful summer picnic with friends and family. We are excited to bring some of our iconic archive prints to this colorful selection of UNIQLO’s easy summer dresses, matching accessories and more. Each item reflects the bol

HiddenA line styled icon from Orion Icon Library.Eye